Taurine prevents haloperidol-induced changes in striatal neurochemistry and behavior.
Repeated daily administration of haloperidol produces changes in striatal neurochemistry (decreased dopamine synthesis, upregulation of D2 receptors) and behavior (increasing catalepsy). Coadministration of taurine greatly attenuated these neuroleptic-induced changes. Possible mechanisms of taurine's mitigating effects are its attenuating influences on glutamatergic transmission and its actions as a GABAA agonist. The possibility was discussed of adding taurine to chronic antipsychotic regimens to block the side-effects typically accompanying such therapy.
Lidsky
T I
TI
Department of Psychobiology, NYS Institute for Basic Research, Staten Island 10314, USA.
Schneider
J S
JS
Yablonsky-Alter
E
E
Zuck
L G
LG
Banerjee
S P
SP
D000818:Animals; D014150:Antipsychotic Agents / Q000037:antagonists & inhibitors*; D002375:Catalepsy / Q000139:chemically induced*; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004334:Drug Administration Schedule; D005069:Evaluation Studies as Topic; D018698:Glutamic Acid / Q000378:metabolism; D006220:Haloperidol / Q000037:antagonists & inhibitors*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013654:Taurine / Q000494:pharmacology*
D014150:Antipsychotic Agents; D013654:Taurine; D018698:Glutamic Acid; D006220:Haloperidol